Literature DB >> 22653635

Outpatient parenteral antibiotic therapy (OPAT) at home in Attica, Greece.

G Theocharis1, P I Rafailidis, D Rodis, I Kontopidis, S G Barbas, M E Falagas.   

Abstract

Outpatient parenteral antibiotic therapy (OPAT) is considered to be a cost-effective and safe alternative treatment strategy to hospitalization. We retrospectively evaluated data regarding the demographic and treatment characteristics of patients that sought medical advice from a network of physicians performing house-call visits and who received OPAT at home during a 17-month period (May 2009 to September 2010) in Attica, Greece. A total of 91 patients (69.2 % females) received intravenous antibiotic therapy at home during the evaluated period. The mean age [± standard deviation (SD)] of the patients was 85.3 (± 9) years. The main indications were pneumonia [46 patients (50.5 %)], urinary tract infection [25 (27.5 %)], and gastrointestinal tract infection [9 (9.9 %)]. Of the patients, 76.4 % received a beta-lactam, 17.5 % a fluoroquinolone, 15.3 % an imidazole, 8.7 % an aminoglycoside, and 5.4 % a lincosamide. The cure rate was 72.5 % and mortality was 27.5 %. The mean duration (± SD) of intravenous antibiotic treatment was 4.7 (± 3.3) days. The mean cost per patient was <euro>637 and was comparable to the mean cost if the patient were to be hospitalized for the same infection. There was significant clinical effectiveness of OPAT at home in this mainly elderly population, at an acceptable cost.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22653635     DOI: 10.1007/s10096-012-1647-1

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  12 in total

1.  Early switch to oral treatment in patients with moderate to severe community-acquired pneumonia: a meta-analysis.

Authors:  Zoe Athanassa; Gregory Makris; George Dimopoulos; Matthew E Falagas
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 2.  Update and overview of outpatient parenteral antimicrobial therapy regulations and reimbursement.

Authors:  Barbara Ross Nolet
Journal:  Clin Infect Dis       Date:  2010-09-15       Impact factor: 9.079

3.  Treatment of various infections in an outpatient practice by intramuscular ceftriaxone: home parenteral therapy.

Authors:  G N Karachalios; A N Georgiopoulos; S Kanatakis
Journal:  Chemotherapy       Date:  1989       Impact factor: 2.544

4.  Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients.

Authors:  Jordi Carratalà; Núria Fernández-Sabé; Lucía Ortega; Xavier Castellsagué; Beatriz Rosón; Jordi Dorca; Ana Fernández-Agüera; Ricard Verdaguer; Joaquín Martínez; Frederic Manresa; Francesc Gudiol
Journal:  Ann Intern Med       Date:  2005-02-01       Impact factor: 25.391

5.  Clinical efficacy and cost-effectiveness of outpatient parenteral antibiotic therapy (OPAT): a UK perspective.

Authors:  Ann L N Chapman; Simon Dixon; Dawn Andrews; Patrick J Lillie; Rohit Bazaz; Julie D Patchett
Journal:  J Antimicrob Chemother       Date:  2009-09-19       Impact factor: 5.790

6.  Outpatient parenteral antibiotic therapy in the elderly: an Italian observational multicenter study.

Authors:  S Esposito; S Leone; S Noviello; F Ianniello; M Russo; G Foti; M S Carpentieri; C Cellesi; G Zanelli; A Cellini; C Girmenia; F De Lalla; A Maiello; P Maio; N Acone; F Marranconi; S Sabbatani; M Pantaleoni; F Ghinelli; M L Soranzo; P Viganò; T Re; P Viale; L Scudeller
Journal:  J Chemother       Date:  2009-04       Impact factor: 1.714

7.  An outpatient parenteral antibiotic therapy (OPAT) map to identify risks associated with an OPAT service.

Authors:  Mark Gilchrist; Bryony Dean Franklin; Jignesh P Patel
Journal:  J Antimicrob Chemother       Date:  2008-04-12       Impact factor: 5.790

8.  Successful treatment of thoracic actinomycosis with ceftriaxone.

Authors:  A Skoutelis; J Petrochilos; H Bassaris
Journal:  Clin Infect Dis       Date:  1994-07       Impact factor: 9.079

Review 9.  Developments in outpatient parenteral antimicrobial therapy (OPAT) for Gram-positive infections in Europe, and the potential impact of daptomycin.

Authors:  Dilip Nathwani
Journal:  J Antimicrob Chemother       Date:  2009-07-07       Impact factor: 5.790

Review 10.  Avoiding hospital admission through provision of hospital care at home: a systematic review and meta-analysis of individual patient data.

Authors:  Sasha Shepperd; Helen Doll; Robert M Angus; Mike J Clarke; Steve Iliffe; Lalit Kalra; Nicoletta Aimonio Ricauda; Vittoria Tibaldi; Andrew D Wilson
Journal:  CMAJ       Date:  2009-01-20       Impact factor: 8.262

View more
  6 in total

1.  Outpatient parenteral antimicrobial therapy.

Authors:  Kevin B Laupland; Louis Valiquette
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

2.  OPAT in Switzerland: single-center experience of a model to treat complicated infections.

Authors:  Andrea Erba; Michelle Beuret; Mary-Louise Daly; Nina Khanna; Michael Osthoff
Journal:  Infection       Date:  2019-12-11       Impact factor: 3.553

Review 3.  Clinical and cost-effectiveness, safety and acceptability of community intravenous antibiotic service models: CIVAS systematic review.

Authors:  E D Mitchell; C Czoski Murray; D Meads; J Minton; J Wright; M Twiddy
Journal:  BMJ Open       Date:  2017-04-20       Impact factor: 2.692

4.  Patient house calls in Attica and Thessaloniki, Greece (2005-2015): a model for out-of-hospital multispecialty emergency medicine.

Authors:  George Theocharis; Spyridon G Barbas; Theodore Spiropoulos; Petroula E Stamouli; Dimitrios N Perdikis; Matthew E Falagas
Journal:  BMC Health Serv Res       Date:  2018-04-27       Impact factor: 2.655

5.  Cost-analysis of inpatient and outpatient parenteral antimicrobial therapy in orthopaedics: A systematic literature review.

Authors:  Christoph Kolja Boese; Philipp Lechler; Michael Frink; Michael Hackl; Peer Eysel; Christian Ries
Journal:  World J Clin Cases       Date:  2019-07-26       Impact factor: 1.337

6.  Consumption of tetracyclines, sulphonamides and trimethoprim, and other antibacterials in the community, European Union/European Economic Area, 1997-2017.

Authors:  Ann Versporten; Robin Bruyndonckx; Niels Adriaenssens; Niel Hens; Dominique L Monnet; Geert Molenberghs; Herman Goossens; Klaus Weist; Samuel Coenen
Journal:  J Antimicrob Chemother       Date:  2021-07-26       Impact factor: 5.790

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.